SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples.
Tamara S RodemsDuane S JuangCharlotte N StahlfeldCole S GilsdorfTim E G KruegerErika HeningerShuang G ZhaoJamie M SpergerDavid J BeebeMichael C HaffnerJoshua M LangPublished in: Clinical epigenetics (2022)
SEEMLIS is a robust assay for targeted DNA methylation analysis in low-input samples, with flexibility at multiple steps. We demonstrate the feasibility of this assay to analyze DNA methylation in prostate cancer cells using CTCs from patients with prostate cancer as a real-world example of a low-input analyte of clinical importance. In summary, this novel assay provides a platform for determining methylation signatures in rare cell populations with broad implications for research as well as clinical applications.